Vijay Kumar Panthi | Medicine and Health Sciences | Best Researcher Award

Published on by Popular Engineer

Mr. Vijay Kumar Panthi | Medicine and Health Sciences | Best Researcher Award

PhD Candidate, Queensland University of Technology, Australia

Vijay Kumar Panthi is a seasoned professional in Pharmaceutics with a focus on drug delivery and formulation. He holds a Master’s degree in Pharmacy (Pharmaceutics) from Mokpo National University, South Korea, and a Bachelor’s degree in Pharmacy from Tribhuvan University, Nepal. With extensive experience in formulation, research, and development, he has worked with several prominent pharmaceutical companies, including Royal Sasa Nepal Pharmaceuticals and Corel Pharmaceuticals. His expertise spans across nanoformulations, drug delivery systems, and formulation development for anticancer and anti-aging treatments. He has also contributed to several publications and conference posters, particularly in the field of nanomedicine, wound healing, and oral drug bioavailability. His research interests center around enhancing drug solubility and permeability, particularly for anticancer and diabetes treatments. He is a registered pharmacist with the Pharmacy Council of Nepal and actively engages in clinical pharmacy training and regulatory affairs.

Profile

Education

Vijay Kumar Panthi completed his Master’s in Pharmacy (Pharmaceutics) from Mokpo National University, South Korea, between 2017-2019. This advanced program deepened his knowledge of drug formulation, nanoformulations, and drug delivery systems. He earned his Bachelor’s degree in Pharmacy from Tribhuvan University, Nepal, at Sunsari Technical College, Dharan, between 2010 and 2014. Additionally, he completed Intermediate studies in Pharmacy at the Nepal Institute of Medical Science and Technology (NIMST), Kathmandu. Before that, he graduated from Mukti Higher Secondary School, Pyuthan, Nepal, in 2005. His academic journey has provided him with a solid foundation in pharmaceutical sciences and research, focusing on developing innovative solutions to improve drug efficacy and bioavailability, particularly in cancer and diabetes therapies.

Experience

Vijay Kumar Panthi has over 10 years of experience in the pharmaceutical industry, spanning formulation development, research, and regulatory affairs. He currently serves as the Manager of Formulation, Research, and Development (FR&D) at Royal Sasa Nepal Pharmaceuticals. Prior to this, he held the same position at Corel Pharmaceuticals Pvt. Ltd., where he developed and tested various drug formulations. His experience also includes conducting formulation and development research at Mokpo National University, South Korea, between 2017 and 2019. Additionally, he worked at Asian Pharmaceuticals Pvt. Ltd., where he contributed to GMP-certified projects, regulatory affairs, and validation processes. He has also participated in industrial training at companies like Everest Pharmaceuticals, Nepal, and Zydus Healthcare, India, which further honed his practical knowledge. Vijay’s diverse experience across multiple pharmaceutical functions highlights his expertise in drug formulation and development, particularly for anticancer and anti-aging applications.

Research Focus

Vijay Kumar Panthi’s primary research interests lie in the formulation of drug delivery systems, particularly for anticancer and diabetes treatments. His work focuses on enhancing the solubility, permeability, and bioavailability of active pharmaceutical ingredients (APIs), particularly those with limited oral bioavailability. In his Master’s thesis, he worked on the co-delivery system of pemetrexed and quercetin via multiple nanoemulsions to improve oral bioavailability and anticancer efficacy. His interest in nanoformulations extends to other therapeutic areas such as wound healing and anti-aging. By utilizing nanoemulsions, liposomes, and hydrogels, Vijay aims to develop novel drug delivery systems that improve the therapeutic outcomes of drugs for various diseases, especially chronic conditions like cancer and diabetes. His research on the formulation of anti-acne treatments and serine protease formulations for inflammation also demonstrates his versatility and commitment to improving patient care through scientific advancements.

Publication Top Notes

  1. Characterization and In Vivo Evaluation of an Oral Multiple Nanoemulsive System for Co-Delivery of Pemetrexed and Quercetin 📚💊
  2. Preparation, Characterization, and Biological Activities of Topical Anti-Aging Ingredients in a Citrus junos Callus Extract 🍊💆‍♂️
  3. Formulation and Development of Adapalene Topical Nanohydrogel Using Different Surfactants and Cosurfactants for Antiacne Activity: In Vitro and Ex Vivo Evaluation 🧴🔬
  4. Enhanced Oral Absorption of Pemetrexed by Ion-Pairing Complex Formation with Deoxycholic Acid Derivative and Multiple Nanoemulsion Formulations 💊🧪
  5. Formulation and Development of Serratiopeptidase Enteric Coated Tablets and Analytical Method Validation by UV Spectroscopy 🧫🔬
  6. A Validated RP-HPLC Method for Simultaneous Determination of Cefixime and Clavulanic Acid Powder in Pediatric Oral Suspension 🧪👶
  7. Preparation and Characterization of Callus Extract From Pyrus pyrifolia and Investigation of Its Effects on Skin Regeneration 🍐🧴
  8. Formulation and Development of Water-in-Oil Emulsion-Based Luliconazole Cream: In Vitro Characterization and Analytical Method Validation by RP-HPLC 🧴🔬

 

 

Alejandra Guillermina Miranda-Díaz | Clinical Research | Women Researcher Award

Published on by Popular Engineer

Prof. Dr. Alejandra Guillermina Miranda-Díaz | Clinical Research | Women Researcher Award

Alejandra Guillermina Miranda Díaz is a distinguished Professor and Researcher with extensive experience in the fields of general surgery, pharmacology, and clinical research. Having pursued a lifelong passion for surgery, she became a Medical Surgeon and Partero at the University of Guadalajara, later specializing in General Surgery and obtaining a Master’s in Medical Sciences and a Doctorate in Pharmacology. Her academic journey reflects a commitment to advancing medical research, particularly in inflammatory diseases and oxidative stress. Miranda Díaz has held significant roles in academia, such as coordinating master’s programs in Medical Sciences and mentoring numerous graduate students. Her expertise has led to collaborations with hospitals and medical professionals on various groundbreaking studies. Her research focuses on understanding the mechanisms of inflammation and oxidative stress, contributing significantly to advancements in clinical pharmacology and surgical practice.

Profile

Education 

Alejandra Guillermina Miranda Díaz’s educational background is rich and diverse, rooted in the University of Guadalajara. She began her academic journey with a Bachelor’s degree in Medicine (1971–1977), followed by an advanced specialization in General Surgery (1983). Driven by a deep interest in medical research, she pursued a Master’s in Medical Sciences (1992), and later, a Doctorate in Pharmacology (2003), solidifying her status as an expert in the field. These academic milestones, supported by a strong foundation in clinical surgery, enabled her to bridge the gap between practical medical procedures and theoretical scientific exploration. Throughout her career, she has been dedicated to applying her educational experience to improve medical knowledge, train future professionals, and contribute to groundbreaking research in fields such as inflammation, oxidative stress, and pharmacology.

Experience 

Alejandra Guillermina Miranda Díaz has dedicated over 40 years to both clinical practice and academic instruction. She began her career as a General Surgeon in the IMSS (Mexican Social Security Institute) in 1983, advancing through various leadership roles such as the Coordinator of the Laparoscopic Surgery Program and Sub-Director of the Medical Morning Shift at Hospital General Regional No. 45. In 2001, she transitioned to academia, becoming a Professor and Researcher in the Department of Physiology at the University of Guadalajara’s Center for Health Sciences. Her role as the Coordinator for various Master’s and Doctorate programs in Medical Sciences allowed her to shape the careers of numerous students. Her expertise has earned her a prominent place in the field, with notable distinctions such as membership in multiple medical associations and the System of National Researchers (SNI), where she holds the level II status until 2026.

Research Focus 

Alejandra Guillermina Miranda Díaz’s research primarily focuses on the role of inflammation and oxidative stress in various diseases, particularly in nephrology and metabolic disorders. Her research examines the complex mechanisms of these processes in conditions such as lupus nephritis, diabetes, and obesity. By studying toll-like receptors (TLRs) such as TLR7 and TLR9, Miranda Díaz explores how these receptors influence disease progression and contribute to inflammatory responses. Her work is pivotal in understanding the broader implications of oxidative stress and inflammation, offering potential therapeutic targets for chronic diseases. Currently, her research includes investigating how inflammation and oxidative stress affect renal function in lupus nephritis and exploring their potential links to metabolic syndrome and obesity. Her work fosters collaboration between medical institutions and researchers, aiming to improve patient care and medical treatment strategies through evidence-based scientific discoveries.

Publication Top Notes

  • The Role of TLRs in Obesity and Its Related Metabolic Disorders 🧬
  • The Expression of Toll-like Receptors (TLR7 and TLR9) in Class III and Class IV of Recently Diagnosed Lupus Nephritis with 12-Month Follow-Up 🧪
  • The Sigma-1 Receptor Exacerbates Cardiac Dysfunction Induced by Obstructive Nephropathy: A Role for Sexual Dimorphism 💖
  • Clinical Impact Using Low Dose Mycophenolate Mofetil with Tacrolimus on Acute Rejection, Infectious Diseases, and Non-Infectious Complications in Renal Transplant: A Single Hospital Experience in Mexico 🏥
  • The Effect of Enalapril, Losartan, or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients 🌱
  • Foods with Potential Prooxidant and Antioxidant Effects Involved in Parkinson’s Disease 🧠
  • The Role of Oxidative Stress in Physiopathology and Pharmacological Treatment with Pro- and Antioxidant Properties in Chronic Diseases ⚖️
  • The Effect of Visceral Abdominal Fat Volume on Oxidative Stress and Proinflammatory Cytokines in Subjects with Normal Weight, Overweight, and Obesity 🏃‍♀️

 

 

Salvador Gonzalez | Skin Cancer Prevention | Best Researcher Award

Published on by Popular EngineerLeave a Comment on Salvador Gonzalez | Skin Cancer Prevention | Best Researcher Award

Prof. Salvador Gonzalez | Skin Cancer Prevention | Best Researcher Award

Clinician/Researcher, Alcalá University, Spain

Dr. Salvador González is an accredited Full Professor at the Quality and Accreditation Evaluation National Agency (ANECA) and an Associate Professor in Medicine at Universidad de Alcalá, Madrid, Spain. He also serves as an advisor in the Dermatology Department at Hospital Ramón y Cajal, Madrid. Dr. González has a remarkable career in dermatology and medical research, having held prestigious academic and clinical positions worldwide. He has taught at renowned institutions such as Harvard Medical School, Memorial Sloan-Kettering Cancer Center, and Universidad de Alcalá. His dedication to advancing dermatology spans clinical practice, teaching, and groundbreaking research. He has been instrumental in photodynamic therapy (PDT), reflectance confocal microscopy, and skin cancer prevention. His expertise has earned him global recognition and a multitude of awards, making him a leading figure in dermatology.

Profile

Scopus

Education

Dr. Salvador González’s academic journey began at the Universidad de Málaga, Spain, where he earned his MD in 1982. His specialization in dermatology was pursued at the Dermatology Department of the same university from 1982 to 1985. He furthered his education with a Diploma in Public Health from the National Health Institute, Madrid, in 1986, and later obtained his Ph.D. in Medicine (Cellular Biology, with a focus on dermatology) from the University of Málaga in 1990. His advanced studies laid the groundwork for his extensive work in medical research and dermatology. Throughout his career, Dr. González has continually expanded his academic horizons through positions at prestigious institutions such as Harvard Medical School, Massachusetts General Hospital, and Memorial Sloan-Kettering Cancer Center, earning global recognition for his expertise in dermatology and his research in skin cancer and innovative medical technologies.

Experience

Dr. Salvador González has an illustrious career spanning over three decades. From 1985 to 1993, he worked as a Clinical Dermatologist for the Penitentiary Health and National Health System in Málaga, Spain. He then pursued significant research in the U.S. as a Beca de Investigación at the Wellman Laboratories of Photomedicine at Massachusetts General Hospital (MGH) from 1993 to 1995. Dr. González’s academic roles include serving as a Dermatology Professor at Harvard Medical School from 1997 to 2000. His academic journey further included being an Assistant Biochemist at MGH, Boston, and an Associate Scientist at Memorial Sloan-Kettering Cancer Center, New York, from 2003 to 2017. He is currently an advisor to the Dermatology Department at Hospital Ramón y Cajal, Madrid, Spain. Dr. González has also held leadership positions in various biopharmaceutical companies, contributing significantly to medical advancements in dermatology, particularly skin cancer and photomedicine.

Awards and Honors

Dr. Salvador González has received numerous prestigious awards and honors throughout his career. In 1999, he was awarded the Alexander A. Fisher Bronze Award by the American Society of Contact Dermatitis. He was named an Honorary Member of the Dermatology Mexican Society and the International Plastic Dermatology Society in 1999 and 2000. He received two Research Awards from The Skin Cancer Foundation in 2000 and 2001. In 2004, Dr. González became an Honorary Member of the Dermatology Academy of Saudi Arabia. His distinguished career has also led to global recognition, including being selected for “Who’s Who” in the USA and being awarded the Melilla’s Year Citizen Award (2005). Notable honors include the 2014 Khosrow Montaz Memorial Lectureship Award from Massachusetts General Hospital, the 2015 Gold Medal from Forum Europe for his contributions to medicine, and the Presidential Citation from the American Academy of Dermatology in 2017 for his work on Reflectance Confocal Microscopy.

Research Focus

Dr. Salvador González’s research focus lies primarily in dermatology, with an emphasis on skin cancer prevention, photodynamic therapy (PDT), and reflectance confocal microscopy. His work has significantly advanced the understanding of basal cell carcinoma, Bowen’s disease, and cutaneous squamous cell carcinoma, particularly in terms of their response to PDT. He has also explored the effects of personalized photoprotection and the impact of blue light on retinal pigment epithelial cells. Dr. González’s research has led to breakthroughs in the clinical application of PDT and new insights into the molecular markers that affect treatment responses. His commitment to advancing non-invasive diagnostic tools, like reflectance confocal microscopy, has revolutionized skin cancer detection. Dr. González continues to lead studies that bridge the gap between basic dermatological science and clinical practice, with a long-term goal of improving patient outcomes and advancing personalized treatments in dermatology.

Publication

  1. Analysis of Tumoral, Stromal, and Glycolytic Markers in the Response of Basal Cell Carcinoma and Bowen Disease to Photodynamic Therapy in Real Life
  2. Personalized Photoprotection: Expert Consensus and Recommendations From a Delphi Study Among Dermatologists
  3. Comparative Response to PDT with Methyl-Aminolevulinate and Temoporfin in Cutaneous and Oral Squamous Cell Carcinoma Cells
  4. The Effect of Fernblock® in Preventing Blue-Light-Induced Oxidative Stress and Cellular Damage in Retinal Pigment Epithelial Cells
  5. Application of Dermoscopy and Reflectance Confocal Microscopy in Vivo in the Evaluation of Nevi in Children
  6. New Trends on Personalized Sunscreens
  7. Reflectance Confocal Microscopy Terminology in Spanish: A Delphi Consensus Study
  8. International Expert Recommendations on Image Acquisition for In Vivo Reflectance Confocal Microscopy of Cutaneous Tumors
  9. The m-TORC1 Inhibitor Sirolimus Increases the Effectiveness of Photodynamic Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma, Impairing NRF2 Antioxidant Signaling
  10. Conventional PDT Versus One PDT Session Plus 3% Diclofenac Gel for Severe Skin Field Cancerization of the Face and Scalp: Randomized Controlled Trial Assessing Clinical and Histological Response

 

 

 

Assoc. Prof. Dr. Gayatri Athalye-Jape | Gut Microbiome | Women Researcher Award

Published on by Popular EngineerLeave a Comment on Assoc. Prof. Dr. Gayatri Athalye-Jape | Gut Microbiome | Women Researcher Award

Assoc. Prof. Dr. Gayatri Athalye-Jape | Gut Microbiome | Women Researcher Award

Consultant neonatal paediatrician, King Edward Memorial Hospital, Australia

Dr. Gayatri Kedar Jape is a distinguished consultant neonatal paediatrician at King Edward Memorial Hospital for Women in Perth, Australia. With extensive expertise in neonatology and paediatrics, her focus encompasses the long-term neurodevelopmental follow-up of preterm infants, gut microbiota-brain axis, probiotics in preterm care, and clinical leadership. She holds several academic titles, including Clinical Associate Professor at the University of Western Australia (UWA) and has been a vital contributor to research on neonatal care and developmental outcomes. Dr. Jape’s leadership roles span various esteemed committees, including the Perinatal Society of Australia and New Zealand, the Global Newborn Society, and the WA Neonatal Network. She has a passion for enhancing staff wellbeing and communication within healthcare settings. Through numerous peer-reviewed publications, clinical trials, and academic mentorship, Dr. Jape has made significant contributions to neonatal health research and education.

Profile

Orcid

Education

Dr. Gayatri Kedar Jape completed her MBBS from the University of Mumbai with honors in 2002. She then pursued her MD in Paediatrics at the same institution, graduating with distinction in 2007. She further expanded her medical knowledge by completing a Fellowship from the Royal Australasian College of Physicians in 2013. Dr. Jape’s academic achievements include certifications in Clinician Performed Ultrasound (2019), a Graduate Certificate in Autism Diagnosis (UWA, 2019), and a Graduate Certificate in Clinical Leadership from UC Davis (2020). Her dedication to advancing neonatal care culminated in a PhD from the University of Western Australia in 2022. Throughout her career, Dr. Jape has continually enriched her expertise, aiming to improve long-term outcomes for preterm infants through her research, clinical care, and teaching roles. Her contributions to the field underscore a strong commitment to integrating innovative solutions into paediatrics.

Experience

Dr. Gayatri Kedar Jape is a consultant neonatal paediatrician at King Edward Memorial Hospital for Women in Perth, where she has been serving since 2015. Her clinical experience spans the complex care of preterm infants, specializing in neonatal nutrition, neurodevelopmental outcomes, and follow-up care. She is also the Clinical Lead of the Neonatal Follow-Up Program at KEMH, focusing on long-term neurodevelopment in preterm infants. Dr. Jape’s leadership extends to high-level roles such as the CAHS Medical Lead for the New Women’s and Babies Hospital Project (2024) and Chair of the PSANZ Long-Term Outcomes Subcommittee (2022–2025). She is deeply engaged in international collaborative efforts, holding executive positions in the Global Newborn Society and the Australian and New Zealand Neonatal Network. In her academic roles at the University of Western Australia, Dr. Jape is shaping the next generation of neonatologists through supervision, lectures, and clinical training.

Research Focus

Dr. Gayatri Kedar Jape’s research focuses on understanding the role of gut microbiota in preterm infants and its link to neurodevelopmental outcomes, particularly autism. She has led clinical trials examining the impact of probiotics on preterm infants, exploring how gut health influences both immediate and long-term health outcomes. Her pioneering studies on probiotics, including the use of single versus multi-strain probiotics, have contributed valuable insights into improving the enteral nutrition of extremely preterm infants. Dr. Jape is also investigating the gut microbiota-brain axis, which has implications for neurodevelopmental disorders. Through her work in neonatal care, she aims to enhance clinical practices and follow-up programs to support the development of preterm infants in the long term. She continues to explore innovative approaches in neonatal nutrition and autism diagnosis, as well as mental health and communication within healthcare teams to foster better staff wellbeing.

Publication Top Notes

  1. Evaluation of Faecal Microbiota Following Probiotics in Infants of Mothers with Gestational Diabetes Mellitus Trial: Protocol for Double-Blind Placebo-Controlled Randomized Trial – Microorganisms 🧬
  2. Effects of a live versus heat-inactivated probiotic Bifidobacterium spp in preterm infants: a randomised clinical trial – Archives of Disease in Childhood – Fetal and Neonatal Edition 🍼
  3. Benefits of routine probiotic supplementation in preterm infants – Acta Paediatrica, International Journal of Paediatrics 🌱
  4. Limosilactobacillus reuteri DSM 17938 as a probiotic in preterm infants: An updated systematic review with meta-analysis and trial sequential analysis – Journal of Parenteral and Enteral Nutrition 💊
  5. Effect of Probiotic Dose Escalation on Gut Microbiota and Clinical Outcomes in Preterm Infants—A Systematic Review – Children 👶
  6. Growth and neuro-developmental outcomes of probiotic supplemented preterm infants—a systematic review and meta-analysis – European Journal of Clinical Nutrition 📈
  7. Therapeutic hypothermia for neonates with sudden unexpected postnatal collapse – Archives of Disease in Childhood ❄️
  8. Localised chorioangiomatosis associated with fetal right-sided cardiac dilatation – Journal of Paediatrics and Child Health ❤️
  9. Association of gastric residual volumes with necrotising enterocolitis in extremely preterm infants—a case–control study – European Journal of Pediatrics 🏥
  10. Outcomes in extremely low birth weight (≤500 g) preterm infants: A Western Australian experience – Early Human Development 🌍